Result: Risk Minimisation Materials for medicines starting with the letter F

Fabrazyme

Genzyme Therapeutics

Fabrazyme (agalsidase beta) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Fabrazyme (agalsidase beta) at home.

For Healthcare Professionals

Fabrazyme (agalsidase beta) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Fabrazyme (agalsidase beta) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

Fabrazyme® (agalsidase beta) - Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Femodene

Bayer plc

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

Femodene ED

Bayer plc

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

Femodette

Bayer plc

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

Fiasp

Novo Nordisk Limited

Direct Healthcare Professional Communication

Risk of mix-ups between insulin Fiasp® (fast-acting insulin aspart) and Tresiba® (basal insulin degludec)

For Healthcare Professionals

Flixabi

Biogen Biosimilars

Flixabi Healthcare Professional Brochure

IMPORTANT INFORMATION FOR HCPs ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB

For Healthcare Professionals

Flixabi Patient Alert Card

This Alert Card contains important safety information that patients need to be aware of before and during treatment with Flixabi.

Flixabi Screening Sheet

This screening sheet is intended for use by HCPs who are assessing patients being considered for infliximab therapy.

For Healthcare Professionals

Forxiga

AstraZeneca UK Limited

Forxiga (dapagliflozin) – Guide for Healthcare Professionals

Guide for Healthcare Professionals to minimise the risk of Diabetic Ketoacidosis (DKA)

For Healthcare Professionals

Forxiga (dapagliflozin) – Patient and carer Guide

For people with type 1 diabetes mellitus and their carers to minimise the risk of Diabetic Ketoacidosis (DKA)

Patient Alert Card

Patient Alert Card

For Healthcare Professionals